Saturday 17 October 2026
Export RGEN’s income statement to Excel — free account
Repligen Corporation
RGEN Healthcare Medical Instruments & Supplies
Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024. In the quarter to June 2026, revenue grew 11.9%, EPS fell 65.4%, free cash flow grew 27.1% and total debt rose 3.25%, each against the same quarter a year earlier.
175.20
8.97
−4.87%
Follow RGEN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
0.08% | 2.40% | 2.51% | 1.99% | |
Piotroski F-Score |
6 | 6 | 7 | 7 | |
| 0.06% | 1.69% | 1.78% | 1.42% | ||
ROIC |
0.03% | 1.83% | 2.16% | 2.18% | |
Return on Tangible Assets |
0.15% | 4.12% | 4.25% | 3.36% | |
Average Days of Receivables |
76.81 | 78.41 | 72.47 | 73.32 | |
Free Cash Flow per Share |
1.87 | 1.63 | 1.86 | 1.96 | |
Free Cash Flow |
105.23 | 91.93 | 104.66 | 110.35 | |
Capital Expenditures |
(25.66) | (25.49) | (26.05) | (24.51) | |
| Other line items | |||||
Cash ROIC |
3.12% | 2.69% | 3.05% | 3.18% | |
Accounts Receivable Turnover |
5.09 | 5.04 | 5.11 | 4.99 | |
Accounts Payable Turnover |
15.13 | 11.33 | 11.70 | 12.40 | |
Inventory Turnover |
2.24 | 2.25 | 2.17 | 2.13 | |
Average Days of Payables |
27.96 | 31.12 | 35.12 | 33.24 | |
Days of Inventory on Hand |
152.32 | 176.75 | 181.65 | 186.65 | |
Tax Rate |
(0.63) | (0.22) | (0.09) | (0.20) | |
Research and Development Expense of Revenue |
7.34% | 7.34% | 7.40% | 7.26% | |
Selling, General and Administrative Expense of Revenue |
38.95% | 39.35% | 38.82% | 38.47% | |
Share Based Compensation of Revenue |
4.38% | 4.42% | 4.41% | 4.24% | |
Interest Coverage |
0.04 | 2.56 | 2.95 | 2.92 | |
Operating CF/Net income |
75.31 | 2.40 | 2.54 | 3.25 | |
Depreciation/Fixed assets |
0.49 | 0.51 | 0.56 | 0.58 | |
Capex/Depreciation |
(0.27) | (0.27) | (0.27) | (0.25) | |
Revenue per Share |
12.58 | 13.13 | 13.55 | 13.92 | |
Operating CF per Share |
2.33 | 2.09 | 2.32 | 2.39 | |
Capex per Share |
(0.46) | (0.45) | (0.46) | (0.43) | |
Capex to Sales |
0.04 | 0.03 | 0.03 | 0.03 |
Columns are period end dates